Loading...
Kaken Pharmaceutical Co., Ltd.
KKPCF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$28.09
$0.00(0.00%)
Kaken Pharmaceutical Co., Ltd. (KKPCF) Financial Performance & Income Statement Overview
Review Kaken Pharmaceutical Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-1.29%
↓ 1.29%
Operating Income Growth
18.94%
↑ 18.94%
Net Income Growth
47.52%
↑ 47.52%
Operating Cash Flow Growth
-72.15%
↓ 72.15%
Operating Margin
22.37%
↑ 22.37%
Gross Margin
62.25%
↑ 62.25%
Net Profit Margin
14.83%
↑ 14.83%
ROE
9.22%
↑ 9.22%
ROIC
13.14%
↑ 13.14%
Kaken Pharmaceutical Co., Ltd. (KKPCF) Income Statement & Financial Overview
Review Kaken Pharmaceutical Co., Ltd.'s (KKPCF) income statement with detailed quarterly and annual figures.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $24.62B | $33.12B | $18.25B | $17.36B |
| Cost of Revenue | $9.53B | $9.07B | $8.20B | $8.68B |
| Gross Profit | $15.09B | $24.05B | $10.05B | $8.68B |
| Gross Profit Ratio | $0.61 | $0.73 | $0.55 | $0.50 |
| R&D Expenses | $4.58B | $2.98B | $3.00B | $4.04B |
| SG&A Expenses | $4.66B | $4.25B | $4.30B | $4.00B |
| Operating Expenses | $9.25B | $7.22B | $7.30B | $8.04B |
| Total Costs & Expenses | $18.78B | $16.29B | $15.50B | $16.72B |
| Interest Income | $0.00 | $0.00 | $4.00M | $2.00M |
| Interest Expense | $0.00 | $0.00 | $5.00M | $4.00M |
| Depreciation & Amortization | $688.25M | $652.00M | $688.25M | $674.00M |
| EBITDA | $6.53B | $17.48B | $3.44B | $1.26B |
| EBITDA Ratio | $0.27 | $0.53 | $0.19 | $0.07 |
| Operating Income | $5.84B | $16.83B | $2.75B | $640.00M |
| Operating Income Ratio | $0.24 | $0.51 | $0.15 | $0.04 |
| Other Income/Expenses (Net) | $945.00M | $35.00M | -$379.00M | -$64.00M |
| Income Before Tax | $6.79B | $16.86B | $2.37B | $576.00M |
| Income Before Tax Ratio | $0.28 | $0.51 | $0.13 | $0.03 |
| Income Tax Expense | $1.90B | $4.33B | $617.00M | -$775.00M |
| Net Income | $4.89B | $12.53B | $1.75B | $1.35B |
| Net Income Ratio | $0.20 | $0.38 | $0.10 | $0.08 |
| EPS | $129.09 | $330.90 | $46.32 | $35.65 |
| Diluted EPS | $129.09 | $330.90 | $46.32 | $35.65 |
| Weighted Avg Shares Outstanding | $37.87M | $37.87M | $37.87M | $37.87M |
| Weighted Avg Shares Outstanding (Diluted) | $37.87M | $37.87M | $37.87M | $37.87M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan